1.62
3.23%
0.07
Entera Bio Ltd stock is traded at $1.62, with a volume of 24,403.
It is up +3.23% in the last 24 hours and down -13.51% over the past month.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.
See More
Previous Close:
$1.55
Open:
$1.55
24h Volume:
24,403
Relative Volume:
0.39
Market Cap:
$58.75M
Revenue:
$134.00K
Net Income/Loss:
$-9.93M
P/E Ratio:
-4.3784
EPS:
-0.37
Net Cash Flow:
$-6.72M
1W Performance:
-10.11%
1M Performance:
-13.51%
6M Performance:
-33.05%
1Y Performance:
+119.18%
Entera Bio Ltd Stock (ENTX) Company Profile
Name
Entera Bio Ltd
Sector
Industry
Phone
972-2-532-7151
Address
KIRYAT HADASSAH, MINRAV BUILDING, JERUSALEM
Compare ENTX with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
ENTX | 1.62 | 58.75M | 134.00K | -9.93M | -6.72M | -0.37 |
VRTX | 448.26 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
REGN | 745.57 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
ARGX | 588.39 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
ALNY | 248.72 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
BNTX | 103.24 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Entera Bio Ltd Stock (ENTX) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Mar-22-21 | Initiated | Aegis Capital | Buy |
Entera Bio Ltd Stock (ENTX) Latest News
Knoll Capital Management, LLC's Strategic Acquisition in Entera Bio Ltd - GuruFocus.com
Entera Bio Ltd. (NASDAQ:ENTX) Short Interest Update - MarketBeat
FY2024 EPS Estimate for Entera Bio Decreased by Analyst - MarketBeat
HC Wainwright Reaffirms Buy Rating for Entera Bio (NASDAQ:ENTX) - MarketBeat
Entera Bio Ltd. (ENTX) Quarterly 10-Q Report - Quartzy
Entera Bio Ltd. (ENTX) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance
Entera Bio Highlights Q3 2024 Financials and FDA Anticipation - TipRanks
Entera Bio Reports Q3 2024 Financial Results and Provides Business Updates - The Manila Times
Short Interest in Entera Bio Ltd. (NASDAQ:ENTX) Drops By 14.4% - MarketBeat
Entera Bio Ltd. (NASDAQ:ENTX) Short Interest Up 38.4% in September - MarketBeat
Entera Bio outlook steady as H.C. Wainwright backs potential of total hip BMD in osteoporosis care - Investing.com Australia
Entera Bio (NASDAQ:ENTX) Rating Reiterated by HC Wainwright - MarketBeat
Are Medical Stocks Lagging Argenx (ARGX) This Year? - Yahoo Finance
ENTX & OPK Stock May Gain Following Positive PK/PD Research Data - MSN
Entera Bio shares hold Buy rating on OXM study success By Investing.com - Investing.com Australia
Entera Bio shares hold Buy rating on OXM study success - Investing.com
Entera Bio's (ENTX) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
Entera Bio and OPKO Health report promising obesity treatment study By Investing.com - Investing.com Australia
Entera Bio and OPKO Health report promising obesity treatment study - Investing.com
Entera Bio And Opko Health Provide Update On Pk/Pd Results Of Oral Oxyntomodulin (Glp-1/Glucagon) Peptide Tablet Candidate For Obesity And Metabolic Disorders - XM
Entera Bio and OPKO Health Provide Update on PK/PD Results of Oral Oxyntomodulin (GLP-1/Glucagon) Peptide - EIN News
Is Entera Bio (ENTX) Stock Outpacing Its Medical Peers This Year? - MSN
Is Entera Bio (ENTX) Outperforming Other Medical Stocks This Year? - MSN
Entera Bio Ltd. (NASDAQ:ENTX) Sees Significant Increase in Short Interest - MarketBeat
We're Keeping An Eye On Entera Bio's (NASDAQ:ENTX) Cash Burn Rate - Yahoo Finance
Entera Bio to Participate in Upcoming Investor and Scientific Conferences - GlobeNewswire
All You Need to Know About Entera Bio (ENTX) Rating Upgrade to Buy - Yahoo Finance
Entera Bio Ltd. Forecasted to Earn Q3 2024 Earnings of ($0.05) Per Share (NASDAQ:ENTX) - Defense World
Entera Bio Ltd. to Post Q3 2024 Earnings of ($0.05) Per Share, HC Wainwright Forecasts (NASDAQ:ENTX) - MarketBeat
Entera Bio Ltd. (NASDAQ:ENTX) Short Interest Down 51.0% in July - MarketBeat
Entera Bio (NASDAQ:ENTX) Releases Earnings Results - MarketBeat
Entera Bio's (ENTX) Buy Rating Reaffirmed at HC Wainwright - MarketBeat
HC Wainwright Reiterates Buy Rating for Entera Bio (NASDAQ:ENTX) - Defense World
Entera Bio Reports Q2 2024 Financial Results and Provides Business Updates - GlobeNewswire
Virtu Financial LLC Invests $37,000 in Entera Bio Ltd. (NASDAQ:ENTX) - Defense World
Entera Bio Ltd expected to post a loss of 6 cents a shareEarnings Preview - XM
The 10 Best Biotech Stocks Under $5 To Buy For September 2024! - The Stock Dork
Entera Bio shareholders approve executive compensation, board appointments - Investing.com
Entera’s EB613, the First Once Daily PTH(1-34) Tablet Treatment Dedicated to Post-Menopausal Women with High Risk Osteoporosis Abstract Selected for Presentation at the ASBMR 2024 Annual MeetingKey SABRE Update Also Expected - StockTitan
Entera Bio (NASDAQ:ENTX) Trading Up 1.9% - MarketBeat
Entera Bio (NASDAQ:ENTX) Stock Price Up 1.9% - Defense World
Entera Bio (NASDAQ:ENTX) & Vericel (NASDAQ:VCEL) Financial Survey - Defense World
Short bowel syndrome Market Positive Outlook: Phase Bio , Orphan Technologies , Zealand Pharma - Newstrail
3 Meme Stocks to Buy and Hold for Potential 300% Returns in 3 Years - Markets Insider
Entera Bio Ltd Stock (ENTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Entera Bio Ltd Stock (ENTX) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Taitel Haya | Director |
Jan 10 '24 |
Buy |
0.77 |
7,615 |
5,864 |
25,615 |
LIEBERMAN GERALD M | Director |
Dec 22 '23 |
Buy |
0.71 |
23,952 |
17,006 |
226,961 |
Toledano Miranda Jayne | Chief Executive Officer |
Dec 22 '23 |
Buy |
0.71 |
23,952 |
17,006 |
110,752 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):